XENE / Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates

VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company more_horizontal

VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical compan more_horizontal

VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company more_horizontal

Xenon Pharmaceuticals has a strong cash position of $652.2M and an estimated cash runway of approximately 3.11 years. The company's financial health i more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in Xenon Pharmaceuticals (XENE). While the effectivenes more_horizontal

Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Sherry Aulin - CFO Ian Morti more_horizontal

Xenon Pharmaceuticals (XENE) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares t more_horizontal

VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company more_horizontal